Market Closed - Euronext Paris 16:35:16 14/06/2024 BST 5-day change 1st Jan Change
86.43 EUR -1.71% Intraday chart for Sanofi -5.16% -3.71%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Transcript : Sanofi Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM
CAC40: declines below 7800 points, weighed down by banks CF
Sanofi, Regeneron Secure US FDA Nod for Kevzara’s Use in Polyarticular Juvenile Idiopathic Arthritis MT
Sanofi: US indication extension for Kevzara CF
Regeneron, Sanofi Gain FDA Approval for Kevzara to Treat Juvenile Idiopathic Arthritis MT
Regeneron, Sanofi Get Expanded FDA OK for Kevzara in Polyarticular Juvenile Idiopathic Arthritis DJ
GSK Starts Appeal Against US State Court Ruling on Zantac Lawsuit MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Has Approves Kevzara® CI
GSK takes first steps to appeal Zantac ruling in Delaware AN
GSK: decisions in the Zantac (ranitidine) litigation CF
GSK Appeals US Judge's Decision to Allow Plaintiff Expert Testimony in Zantac Litigation MT
GSK Files Application Seeking Right Of Appeal To Delaware Supreme Court On Zantac Litigation RE
Latest trial over Zantac cancer claims called off as plaintiff drops case RE
Moderna COVID/flu combo vaccine superior to separate shots in trial RE
Ipsen Hires New Chief Corporate Affairs Officer MT
Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada MT
Lupin Atlantis Holdings SA completed the acquisition of selection of established products in Europe and Canada from Sanofi. CI
CAC40: further decline, W-Street heavier, 'WTI' below $73 CF
CAC40: losses trimmed as oil falls below $78 and interest rates ease CF
Charles River Laboratories, Sanofi Collaborating to Develop Non-Animal Virtual Control Groups for Preclinical Trials MT
SANOFI : UBS reiterates its Buy rating ZD
Sanofi: positive phase III data in myeloma CF
Sanofi's Blood Cancer Drug Sarclisa Meets Primary, Secondary Endpoints in Phase 3 Trial MT
DHL Strikes Logistics Partnership with Sanofi MT
SANOFI : Gets a Neutral rating from JP Morgan ZD
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
86.43 EUR
Average target price
108.2 EUR
Spread / Average Target
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.